Bli medlem
Bli medlem

Du är här


Biocartis Group NV: Results of the annual general meeting held on 13 May 2016


Results of the ANNUAL GENERAL MEETING held on 13 may 2016

Mechelen, Belgium, 13 May 2016
- Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics
company (Euronext Brussels: BCART), held its annual general shareholders'
meeting ('AGM') in Mechelen today. The shareholders approved all items on the
agenda of the AGM, including the appointment of Mrs. Hilde Eylenbosch as new
independent director, as well as the re-appointment as director of Messrs.
Roald Borré and Rudi Mariën (acting through Gengest BVBA).

----- END ----

For more information, please contact:

Renate Degrave, Corporate Communications&Investor Relations
+32 15 631 729

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has four oncology tests and one test for infectious diseases on the market.
More information: Follow us on Twitter:@Biocartis_.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.